The Expression and Clinical Significance of Different Forms of Mer Receptor Tyrosine Kinase in Systemic Lupus Erythematosus

Table 3

mMer and sMer levels in the presence or absence of manifestations in SLE with the studied parameters.

Manifestations	mMer (MFI)			sMer (pg/mL)
	Presence (𝑛)	Absence (𝑛)	𝑃	Presence (𝑛)	Absence (𝑛)	𝑃
SLEDAI	𝟐𝟎.𝟏𝟗±𝟑.𝟏𝟏	𝟒.𝟒𝟐±𝟎.𝟔𝟒	0.0001***	𝟐𝟒𝟏𝟐.𝟖±𝟐𝟐𝟏.𝟑𝟒	𝟏𝟕𝟓𝟕.𝟗±𝟐𝟐𝟐.𝟐𝟑	0.019*
	(SLEDAI ≥ 8, 𝑛=16)	(SLEDAI < 8, 𝑛=26)		(SLEDAI ≥ 8, 𝑛=59)	(SLEDAI < 8, 𝑛=49)
proteinuria	26.72±3.34	28.02±5.65	0.835	𝟐𝟓𝟖𝟐.𝟑±𝟐𝟐𝟓.𝟏𝟐	𝟏𝟒𝟒𝟏.𝟓±𝟏𝟑𝟗.𝟒𝟗	<0.0001***
	(𝑛=28)	(𝑛=14)		(𝑛=69)	(𝑛=39)
Leukocytopenia	𝟑𝟔.𝟏𝟒±𝟔.𝟔𝟔	𝟐𝟐.𝟔𝟔±𝟐.𝟒𝟒	0.025*	2412±293.28	2044.4±190.94	0.28
	(𝑛=14)	(𝑛=28)		(𝑛=37)	(𝑛=71)
Thrombocytopenia	34.01±7.81	25.54±3.04	0.253	1699.5±268.83	2304.8±190.2397	0.118
	(𝑛=8)	(𝑛=34)		(𝑛=24)	(𝑛=84)
Anti-dsDNA Ab	29.16±4.58	26.17±3.70	0.634	2238.4±246.8	2109.4±211.87	0.691
	(𝑛=14)	(𝑛=28)		(𝑛=51)	(𝑛=57)
ACL	20.61±5.67	28.24±3.21	0.36	2124.6±313.33	2184.8±188.17	0.874
	(𝑛=6)	(𝑛=36)		(𝑛=26)	(𝑛=82)
AnuA	28.36±4.38	26.33±3.88	0.734	2254.4±243.24	2083.1±210.87	0.597
	(𝑛=17)	(𝑛=25)		(𝑛=55)	(𝑛=53)
SSA	𝟑𝟕.𝟎𝟔±𝟒.𝟏𝟕	𝟏𝟔.𝟐𝟓±𝟐.𝟏𝟑	0.0001***	𝟑𝟏𝟗𝟔±𝟐𝟔𝟕.𝟕𝟓	𝟏𝟒𝟑𝟕.𝟕±𝟏𝟑𝟗.𝟒𝟓	<0.0001***
	(𝑛=22)	(𝑛=20)		(𝑛=45)	(𝑛=63)
Sm	𝟑𝟔.𝟗𝟔±𝟒.𝟖𝟒	𝟐𝟏.𝟏𝟐±𝟑.𝟎𝟖	0.006**	𝟑𝟏𝟐𝟑.𝟔±𝟐𝟖𝟒.𝟖𝟓	𝟏𝟖𝟔𝟖.𝟏±𝟏𝟖𝟎.𝟎𝟎	0.001***
	(𝑛=16)	(𝑛=26)		(𝑛=26)	(𝑛=82)
Decreased C3	26.91±3.2	27.94±6.70	0.881	2246.8±184.53	1887.7±325.49	0.363
	(𝑛=32)	(𝑛=10)		(𝑛=85)	(𝑛=23)
Decreased C4	24.21±3.1	32.46±5.72	0.218	2345.4±226.36	1887.7±325.49	0.117
	(𝑛=27)	(𝑛=15)		(𝑛=68)	(𝑛=40)
Increased CRP	27.65±4.08	27±3.59	0.925	2387.1±352.56	2083±176.07	0.395
	(𝑛=10)	(𝑛=32)		(𝑛=31)	(𝑛=55)
Lupus nephritis	𝟑𝟑.𝟐𝟗±𝟒.𝟎𝟕	𝟏𝟖.𝟏𝟐±𝟐.𝟕𝟐	0.004**	𝟐𝟕𝟑𝟕.𝟏±𝟐𝟒𝟖.𝟐𝟏	𝟏𝟕𝟒𝟗.𝟖±𝟏𝟗𝟔.𝟑𝟒	0.002**
	(𝑛=25)	(𝑛=17)		(𝑛=46)	(𝑛=62)

SLE: systemic lupus erythematosus; SLEDAI: systemic lupus erythematosus disease activity index; mMer: membrane Mer tyrosine kinase; sMerTK: soluble Mer tyrosine kinase; MFI: mean fluorescence intensity; Anti-dsDNA Ab: anti-double strand DNA antibody; ACL: anticardiolipin antibody; AnuA: antinucleosome antibody; SSA: anti-SSA antibody; Sm: anti-Sm antibody; C3: Complement component 3; C4: Complement component 4. CRP: C-reactive protein. An independent Student’s 𝑡-test was used for statistical comparison of mMer and sMer levels between the presence and absence of manifestations group in SLE. *𝑃<0.05, **𝑃<0.01, and ***𝑃<0.001.